NIP
AERI

Nicholas Investment Partners’s Aerie Pharmaceuticals AERI Stock Holding History

Nicholas Investment Partners’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-74,041
Closed -$3.52M – 243
2019
Q1 		$3.52M Buy
+74,041
New +$3.26M 0.31% 107
2017
Q4 		– Sell
-71,871
Closed -$3.49M – 282
2017
Q3 		$3.49M Buy
71,871
+71
+0.1% +$3.87K 0.24% 139
2017
Q2 		$3.77M Sell
71,800
-10,559
-13% -$492K 0.27% 127
2017
Q1 		$3.73M Buy
+82,359
New +$3.67M 0.26% 133

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Nicholas Investment Partners's AERI Position: Q2 2019 in Review

Nicholas Investment Partners sold out of Aerie Pharmaceuticals (AERI) in Q2 2019, closing a stake of 74,041 shares — an estimated $3.52M sold.

Nicholas Investment Partners first reported a position in AERI in Q1 2017 and held it in 4 quarters. The position peaked at $3.77M in Q2 2017. 167 funds tracked by Wall St. Rank hold AERI as of Q2 2019.

  • Nicholas Investment Partners reported no remaining Aerie Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Nicholas Investment Partners sold 74,041 Aerie Pharmaceuticals shares in Q2 2019, an estimated $3.52M.
  • Nicholas Investment Partners first reported a position in Aerie Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • Nicholas Investment Partners's Aerie Pharmaceuticals position peaked at $3.77M in Q2 2017.
  • 167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2019.

Based on Nicholas Investment Partners's 13F filing for Q2 2019, filed 9 Aug 2019.